Latest Innovation News

Nexion Group has completed the sale of its Networks businesses and is pivoting to focus on data centre operations and its FuseAI software platform, preparing for an ASX relisting.

Richmond Vanadium Technology Ltd continues to push forward with its Richmond–Julia Creek Vanadium Project, progressing environmental approvals and technical collaborations despite subdued vanadium market conditions.

NuEnergy Gas Limited has completed drilling four wells at its Tanjung Enim project, gearing up for initial gas sales in the first half of FY26. The company also inked key agreements to finance and expand its coal bed methane operations in Indonesia.

Orbital Corporation Ltd reports a stronger cash position and a strategic new order for its 350cc heavy fuel engine, signalling growth in both military and commercial UAV markets.

Red Metal Limited reports significant technical progress in rare earth processing at its Sybella project alongside advancing gold and copper exploration across multiple Australian sites. The company’s strategic stake in Maronan Metals gains momentum amid rising metal prices.

Aeris Environmental Ltd has reported strong commercial momentum with its Syncromesh IoT platform and specialty chemicals, highlighted by initial orders from Budweiser APAC and a growing purchase order pipeline exceeding $800,000.

Neurizon Therapeutics has locked in a $6 million cash rebate from the Australian Government’s R&D Tax Incentive, underpinning its upcoming HEALEY ALS Platform Trial with first patient dosing slated for early 2026.

ASF Group Limited closed December 2025 with $1.91 million in cash and nearly four quarters of funding runway, while progressing key investments in mining, technology, and biotech sectors.

Platformo Ltd’s Biztrak software arm returned to positive cash flow and profitability in Q4 2025, driven by strategic cost control and digital expansion despite regulatory headwinds in Malaysia.

Immutep Limited has entered a strategic collaboration with Dr. Reddy’s, receiving a A$30 million upfront payment and potential milestones up to A$528 million, while reporting promising clinical progress across multiple cancer immunotherapy trials.

Assetora Limited has strengthened its financial footing by securing over $4 million in capital commitments and resolving all legacy administration matters, positioning itself for a potential ASX reinstatement.

Bioxyne Limited has delivered a record-breaking second quarter in FY2026, posting $17.2 million in revenue and expanding its footprint into key international markets. The company’s growth is underpinned by new contracts, innovative psychedelics products, and strategic government funding.